(Q37810215)

23 August 2017

title

Unwanted immunogenicity: lessons learned and future challenges (English)

1 reference

23 August 2017

1 reference

Meenu Wadhwa

1

1 reference

23 August 2017

Robin Thorpe

series ordinal

2

1 reference

23 August 2017

language of work or name

1 reference

1 June 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

1073-1084

1 reference

Thrombocytopenia caused by the development of antibodies to thrombopoietin

23 August 2017

cites work

1 reference

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

The molecular mechanisms of immunomodulation and tolerance induction to factor VIII.

21 January 2018

1 reference

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

21 January 2018

1 reference

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

21 January 2018

1 reference

Immunogenicity screening in protein drug development.

21 January 2018

1 reference

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

21 January 2018

1 reference

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

21 January 2018

1 reference

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics

21 January 2018

1 reference

Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals

21 January 2018

1 reference

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

21 January 2018

1 reference

The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay.

21 January 2018

1 reference

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

21 January 2018

1 reference

Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).

21 January 2018

1 reference

Survey of the year 2007 commercial optical biosensor literature

21 January 2018

1 reference

Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum

21 January 2018

1 reference

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

21 January 2018

1 reference

Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies

21 January 2018

1 reference

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta

21 January 2018

1 reference

A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression

21 January 2018

1 reference

A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum

21 January 2018

1 reference

Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin

21 January 2018

1 reference

The detection of anti-erythropoietin antibodies in human serum and plasma: part II. Validation of a semi-quantitative 3H-thymidine uptake assay for neutralizing antibodies

21 January 2018

1 reference

Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA.

21 January 2018

1 reference

Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.

21 January 2018

1 reference

Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein

21 January 2018

1 reference

Development and Validation of a Quasi-Quantitative Bioassay for Neutralizing Antibodies Against CP-870,893.

21 January 2018

1 reference

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

21 January 2018

1 reference

Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.

21 January 2018

1 reference

Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.

21 January 2018

1 reference

Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/BIO.10.54

1 reference

23 August 2017

1 reference